PathAI reports algorithm on par in PD-L1 immunotherapy studies

By staff writers

November 7, 2019 -- PathAI reported that its pathology artificial intelligence (AI) algorithm performed on par or better than board-certified pathologists in retrospective immunotherapy studies slated for release on November 9 at the Society for Immunotherapy of Cancer (SITC) annual meeting.

The analyses were conducted with Bristol-Myers Squibb (BMS) and tested the algorithm retrospectively in samples from trials of BMS' programmed cell death ligand 1 (PD-L1) inhibitor nivolumab (Opdivo).

In a study of 1,079 samples from pivotal trials of Opdivo in non-small cell lung cancer, AI-powered and manual quantification showed similar associations between biomarker expression on tumor and immune cells and progression-free survival.

In a separate validation study (see images) of 293 pretreatment samples from patients with metastatic urothelial cancer enrolled in Opdivo studies, evaluation of PD-L1 on immune cells with the AI approach was more in line with a reference standard -- defined as consensus among five pathologists -- than performance of individual pathologists.

Performance with AI and by individual pathologists both correlated with the reference standard when it came to evaluating PD-L1 status on tumor cells, the companies reported. The researchers noted that moderate to poor interobserver agreement among pathologists for PD-L1 on immune cell scoring has been demonstrated in other studies.

Analysis by pathologists and PathAI algorithm
Left: Annotations are captured from multiple pathologists, who label every positive cell in a small "frame" of the slide. Middle: Results of the PathAI algorithm predicting which cells are positive. Right: Annotations and algorithm results are combined, allowing analysis to determine agreement. Images courtesy of PathAI.

PathAI also announced it has obtained $15 million in strategic investments from the Merck Global Health Innovation Fund and Bristol-Myers Squibb. In April, the company said it raised $60 million in a series B financing round led by venture capital firms with LabCorp. Funding from Merck and BMS complete series B, the company said. Overall, PathAI has raised $90 million since its launch in 2016.

Growing AI healthcare market boasts variety of deployments
Bruce Carlson, publisher of Kalorama Information, charts the growth of artificial intelligence (AI) applications in healthcare. The global market is set...
AI algorithm can accurately diagnose appendicitis
By analyzing lab values and ultrasound data, an artificial intelligence (AI) algorithm can be highly accurate for diagnosing acute appendicitis and could...
AI wins some -- and loses some -- in test against pathologists
A novel artificial intelligence (AI) algorithm outperformed pathologists in differentiating ductal carcinoma in situ from atypical hyperplasia, a job...
Video from AACC 2019: What's the future of AI in lab medicine?
ANAHEIM, CA - How will artificial intelligence (AI) affect laboratory medicine in the years to come? AI has been a hot topic at the American Association...
Pathology AI developer PathAI raises $60M
Pathology artificial intelligence (AI) software developer PathAI has raised $60 million in a series B funding round.

Copyright © 2019

Last Updated np 11/6/2019 2:52:34 PM